- Drugs
- Wednesday, 15 Apr 2020
UnitedHealth rises on 'minimal' COVID-19 impact on results & maintained its forecast
UnitedHealth Group Inc on Wednesday reported a better-than-expected quarterly profit due to strength in the pharmacy benefit business and maintained its forecast for the year, sending the company’s shares up nearly 3% before the bell.
UnitedHealth, the first health insurer to report results this earnings season, said its quarterly numbers reflect minimal impact from COVID-19 as the U.S. incidence of the fast-spreading respiratory illness worsened only late in the quarter.
The company said Andrew Witty, head of UnitedHealth’s pharmacy benefit unit, Optum, will take a leave of absence to help lead the World Health Organization’s new initiative for COVID-19 vaccine development.
UnitedHealth said it will continue to evaluate the impact of COVID-19 as the year progresses.
“UNH’s outlook demonstrates how well protected managed care sector earnings will be from the COVID-19 crisis in near term from the unprecedented restrictions on elective health care,” Stephens analyst Scott Fidel said.
The largest U.S. health insurer said it continues to expect adjusted net earnings of $16.25 to $16.55 per share for the year, the mid-point of which is above analysts’ estimate of $16.22, according to Refinitiv IBES data.
Health insurers including UnitedHealth, Cigna Corp and Anthem Inc have announced measures to reduce patient cost sharing on COVID-19 testing and care.
For the quarter ended March 31, earnings attributable to UnitedHealth shareholders fell 2.5% to $3.38 billion, or $3.52 per share, hurt by a 7.1% jump in operating expenses.
Related Industry Updates
South & Central America Gastrointestinal Drugs Market: Business Growth, Development Factors, Applications, and Future Prospects
Dec 15, 2020
Impairment of Cannabis in Safety Sensitive Positions
Oct 21, 2019
FDA Clears ACCRUFeR® (ferric maltol) for Iron Deficiency
Feb 18, 2026
Fluorine-18 Market is expected to reach US$ 2.41billion by 2030
Feb 06, 2024
Bird Flu Virus: Risks, Symptoms, and Vaccines to Stay Safe
Feb 13, 2026
North America Radiopharmaceutical Theragnostic Market is expected to reach US$ 1,529.88 million by 2028
Mar 13, 2023
Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient
Jun 29, 2020